A clinically meaningful progression-free survival benefit (PFS) was observed with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) plus pertuzumab (Perjeta), despite prior treatment, hormone receptor status, or PIK3CA mutations, when compared…
Subgroup Analysis Yields Clinically Meaningful Responses With T-DXd in HER2+ Breast Cancer
